证券简称：海顺新材 证券代码：300501 上海海顺新型药用包装材料股份有限公司 2024 年员工持股计划 （草案） 二〇二四年十月 上海海顺新型药用包装材料股份有限公司 2024 年员工持股计划（草案） 声明 本公司及董事会全体成员保证本员工持股计划的内容真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司 2024 年员工持股计划（草案） 风险提示 一、本员工持股计划须经公司股东大会批准后方可实施，后续能否获得公司 股东大会批准尚存在不确定性； 二、有关本员工持股计划的资金来源、出资比例、实施方案等属初步方案， 本员工持股计划能否完成实施，存在不确定性； 三、员工遵循依法合规、自愿参与、风险自担的原则参与本员工持股计划。 若员工认购金额较低时，本员工持股计划存在低于预计规模的风险； 四、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 3 上海海顺新型药用包装材料股份有限公司 2024 年员工持股计划（草案） 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 一、《上海海顺新型药用包装材料股份有限公司2024年员工持股计划（草 ...

Core Viewpoint - Haishun New Materials (300501.SZ) reported a solid performance in Q3 2023, with significant growth in revenue and net profit, indicating strong market positioning in the pharmaceutical packaging sector [1] Financial Performance - For the first three quarters, the company achieved a revenue of 826 million yuan, a year-on-year increase of 9.03% [1] - The net profit attributable to shareholders was 79.72 million yuan, up 5.14% year-on-year, while the net profit excluding non-recurring items reached 74.06 million yuan, marking a 29.81% increase [1] - In Q3 alone, total revenue was 276 million yuan, reflecting a 20.03% year-on-year growth, and the net profit excluding non-recurring items was 24.85 million yuan, up 42.76% [1] - Basic earnings per share stood at 0.42 yuan [1] Industry Outlook - According to Grand View Research, the global pharmaceutical packaging market is expected to reach 127 billion USD by 2024, growing nearly 40% since 2019, with a compound annual growth rate of approximately 7.5% [1] - The domestic market is highlighted as a key area in Asia, benefiting from a large population base, increasing healthcare demands, and government investments in healthcare systems [1] Company Positioning and Innovation - As a leading company in the domestic pharmaceutical packaging sector, Haishun New Materials emphasizes technological innovation, holding 160 patents, including 21 invention patents, and is at the forefront of technology development in high-barrier and recyclable composite materials [1] - The company has accelerated the development of new high-performance products this year, with several products entering testing and review stages, which will enhance its competitiveness in the pharmaceutical packaging market [1] - Some of the company's R&D projects have been recognized as key projects in Suzhou, reflecting its strength and recognition in technological innovation [1] Market Expansion and Partnerships - The company has successfully expanded its domestic and international markets, establishing a broad sales network and maintaining good relationships with over 80 of the top 100 domestic pharmaceutical companies [1] - Haishun New Materials has received high recognition from well-known pharmaceutical companies, including Pfizer, AstraZeneca, Huahai Pharmaceutical, and Federal Pharmaceutical, further enhancing its brand influence [1] Dividend Announcement - The company announced a cash dividend plan for the first three quarters, proposing to distribute 2.7 yuan per 10 shares (including tax), totaling 50.85 million yuan, which is a historical high [1] - Since its listing in 2016, Haishun New Materials has conducted 10 cash dividend distributions, with a cumulative net profit of 797.50 million yuan and total cash dividends amounting to 246.38 million yuan, resulting in a dividend payout ratio of 30.89% [1]

| 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2024-126 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 关于举办2024年第三季度报告业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 已于 2024 年 10 月 22 日在巨潮资讯网上披露了《2024 年第三季度报 告》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战 略等情况，公司定于 2024 年 10 月 25 日（星期五）15:00-16:00 在 "价值在线"（www.ir-online.cn）举办上海海顺新型药用包装材料 股份有限公司 2024 年第三季度报告业绩说明会，与投资者进行沟通 和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2024 年 10 月 25 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） ...

Revenue and Profit - Revenue for the third quarter was RMB 276.31 million, a 20.03% increase year-over-year[3] - Net profit attributable to shareholders for the third quarter was RMB 21.86 million, a 33.56% decrease year-over-year[3] - Revenue for the period reached 826,447,909.29 yuan, an increase from 758,017,323.85 yuan in the previous period[16] - Net profit attributable to parent company shareholders was 79,722,275.90 yuan, compared to 75,825,343.85 yuan in the previous period[17] - Basic earnings per share stood at 0.42 yuan, up from 0.39 yuan in the prior period[18] Cash Flow - Operating cash flow for the first three quarters was RMB 131.49 million, a 3,322.41% increase year-over-year[3] - Net cash flow from operating activities soared by 3,322.41% to 131,487,187.89 RMB, driven by increased sales cash flow and higher government subsidies[7] - Cash flow from operating activities was 131,487,187.89 yuan, a significant increase from 3,841,952.56 yuan in the previous period[19] - Cash received from investment recoveries surged by 315.13% to 288,952,388.00 RMB, mainly due to increased recovery of financial products[7] - Cash paid for investments increased by 258.64% to 390,931,388.00 RMB, primarily due to higher purchases of financial products[7] - Net cash flow from financing activities decreased by 138.20% to -224,669,581.83 RMB, mainly due to the reduction in funds received from convertible bond issuance compared to the previous year[7] - Net increase in cash and cash equivalents decreased by 217.86% to -335,193,972.00 RMB, primarily due to reduced funds from convertible bond issuance[8] - Cash received from investment activities was 289,712,418.74 yuan, a significant increase from 70,232,116.84 yuan in the prior period[19] - Investment cash outflow totaled $529.19 million, compared to $381.76 million in the previous period[20] - Net cash flow from investment activities was -$239.48 million, compared to -$311.52 million in the previous period[20] - Cash received from borrowings was $89.70 million, compared to $116.17 million in the previous period[20] - Cash received from other financing activities was $4.75 million, compared to $633.85 million in the previous period[20] - Total cash inflow from financing activities was $94.45 million, compared to $750.02 million in the previous period[20] - Cash used for debt repayment was $211.37 million, compared to $142.97 million in the previous period[20] - Cash used for dividend, profit distribution, or interest payment was $47.75 million, compared to $18.41 million in the previous period[20] - Net cash flow from financing activities was -$224.67 million, compared to $588.14 million in the previous period[20] - Net increase in cash and cash equivalents was -$335.19 million, compared to $284.39 million in the previous period[20] Assets and Liabilities - Total assets at the end of the third quarter were RMB 2.93 billion, a 1.96% decrease compared to the end of the previous year[3] - Fixed assets increased by 74.41% to RMB 902.27 million due to the transfer of construction in progress to fixed assets[6] - Construction in progress decreased by 49.27% to RMB 296.42 million due to the transfer to fixed assets[6] - Prepaid expenses increased by 118.27% to RMB 20.16 million due to increased prepayments for goods[6] - Contract liabilities increased by 115.05% to RMB 20.58 million due to increased advance payments from customers[6] - Long-term loans decreased by 73.63% to RMB 19.70 million due to repayments[6] - Total assets decreased to 2,928,079,977.57 yuan from 2,986,593,236.85 yuan at the beginning of the period[13] - Current assets decreased to 1,176,824,570.19 yuan from 1,326,927,116.09 yuan at the beginning of the period[13] - Non-current assets increased to 1,751,255,407.38 yuan from 1,659,666,120.76 yuan at the beginning of the period[13] - Total liabilities decreased to 1,019,686,820.21 yuan from 1,063,708,777.73 yuan at the beginning of the period[14] - Current liabilities decreased to 426,913,814.10 yuan from 456,960,777.15 yuan at the beginning of the period[14] - Non-current liabilities decreased to 592,773,006.11 yuan from 606,748,000.58 yuan at the beginning of the period[14] - Total equity decreased to 1,908,393,157.36 yuan from 1,922,884,459.12 yuan at the beginning of the period[15] - Equity attributable to the parent company decreased to 1,822,479,005.68 yuan from 1,831,064,236.93 yuan at the beginning of the period[15] - Minority interest decreased to 85,914,151.68 yuan from 91,820,222.19 yuan at the beginning of the period[15] Expenses and Income - Taxes and surcharges increased by 37.40% to 7,467,555.21 RMB, mainly due to increases in property tax and land use tax[7] - Financial expenses surged by 90.85% to 21,268,097.84 RMB, primarily due to increased amortization costs from convertible bond issuance[7] - Interest income rose by 33.90% to 12,077,631.17 RMB, driven by higher interest income during the period[7] - Other income increased by 104.29% to 13,193,430.21 RMB, mainly due to higher government subsidies received[7] - Operating costs amounted to 741,453,727.58 yuan, up from 671,259,683.41 yuan in the prior period[16] - Sales revenue from goods and services was 747,899,984.06 yuan, up from 684,793,493.95 yuan in the prior period[19] - Cash received from tax refunds was 19,257,004.05 yuan, down from 22,573,268.58 yuan in the previous period[19] - Cash paid for goods and services was 480,467,511.22 yuan, a decrease from 518,920,580.35 yuan in the prior period[19] - Cash paid to employees and for employee benefits was 119,149,033.07 yuan, up from 107,548,532.05 yuan in the previous period[19] Government Subsidies and Other Income - Government subsidies received during the reporting period amounted to RMB 3.50 million[4] - Other income increased by 104.29% to 13,193,430.21 RMB, mainly due to higher government subsidies received[7] Shareholders and Equity - The number of ordinary shareholders at the end of the reporting period was 14,011, with Lin Wuhui holding the largest stake at 29.98%[9] - Total equity decreased to 1,908,393,157.36 yuan from 1,922,884,459.12 yuan at the beginning of the period[15] - Equity attributable to the parent company decreased to 1,822,479,005.68 yuan from 1,831,064,236.93 yuan at the beginning of the period[15] - Minority interest decreased to 85,914,151.68 yuan from 91,820,222.19 yuan at the beginning of the period[15] Audit and Reporting - The company's third-quarter report was unaudited[21]

一、召开会议基本情况 1、股东大会届次：2024年第五次临时股东大会 | | | 上海海顺新型药用包装材料股份有限公司 关于召开2024年第五次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2024年10月21日召开了第五届董事会第二十九次会议，会议决定于 2024年11月8日（星期五）召开公司2024年第五次临时股东大会。本 次股东大会采用现场投票、网络投票相结合的方式进行，现发布关于 召开公司2024年第五次临时股东大会通知如下： 2、股东大会召集人：公司董事会 3、会议召开的合法性及合规性： 公司于2024年10月21日召开的第五届董事会第二十九次会议，审 议通过《关于提请召开公司2024年第五次临时股东大会的议案》。本 次股东大会的召集程序符合《公司法》《上市公司股东大会规则》等 法律、规范性文件及《公司章程》的相关规定。 4、会议召开方式：本次股东大会采取现场投票与网络投票相结 合的方式。 公司股东应选择现场投票、网络投票中的一种方式，不能重复投 票。如果同一表决票出现 ...

| 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2024-128 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 公司编制的《2024 年第三季度报告》的程序符合法律、行政法 规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：同意票 3 票；反对票 0 票；弃权票 0 票。 2、审议《关于公司 2024 年前三季度利润分配预案的议案》； 一、 监事会会议召开情况 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 第五届监事会第二十一次会议于2024年10月21日以现场加通讯的方 式召开。本次会议应出席监事3人，实际出席监事3人，财务总监、董 事会秘书列席会议。会议的内容以及召集、召开的方式、程序均符合 《公司法》和《公司章程》的规定。 二、 监事会会议审议情况 经与会监事认真审议，通过了以下议案： 1、审议《关于<2024 年第三季度报告>的议案》； 第五届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信 ...

证券代码：300501 证券简称：海顺新材 公告编号：2024-127 债券代码：123183 债券简称：海顺转债 上海海顺新型药用包装材料股份有限公司 第五届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2024年10月11日以电话、微信、电子邮件等方式发出召开第五届董 事会第二十九次会议的通知，会议于2024年10月21日以现场加通讯会 议方式召开，应出席董事7人，实际出席董事7人，监事和高级管理人 员列席会议。本次董事会会议的召集、召开和表决程序符合《公司法》 等法律、法规及《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 经与会董事认真审议，通过了以下议案： 1、审议《关于<2024 年第三季度报告>的议案》； 公司编制的《2024 年第三季度报告》的程序符合法律、行政法规 和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实 际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：同意票 7 票；反对票 0 票 ...

为贯彻落实《国务院关于加强监管防范风险推动资本市场高质量 发展的若干意见》关于推动一年多次分红等政策要求，进一步提高分 红频次，增强投资者回报水平，根据《上市公司监管指引第3号—— | 证券代码：300501 | 证券简称：海顺新材 公告编号：2024-124 | | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | 上海海顺新型药用包装材料股份有限公司 关于2024年前三季度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2024年10月21日召开了第五届董事会第二十九次会议和第五届监 事会第二十一次会议，审议通过了《关于公司2024年前三季度利润分 配预案的议案》，现将相关事宜公告如下： 一、2024年前三季度利润分配预案情况 根据公司2024年第三季度报告（未经审计），公司2024年前三季 度实现归属于上市公司股东的净利润为79,722,275.90元。截至2024 年9月30日，母公司报表可供分配利润为330,155,763.32元，公司合 并 ...

（一）审议通过《关于公司2024年前三季度利润分配预案的议案》 公司拟定的《2024 年前三季度利润分配预案》预案符合《公司 章程》及相关会计准则规定，该预案结合了公司经营发展实际情况， 体现了公司对股东的回报，维护了中小投资者的合法权益。因此，我 们同意该利润分配预案，并同意将该预案提交公司董事会、股东大会 上海海顺新型药用包装材料股份有限公司 第五届董事会独立董事专门会议2024年第六次会议决议 一、独立董事专门会议召开情况 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 第五届董事会独立董事专门会议 2024 年第六次会议（以下简称"独 立董事专门会议"）于 2024 年 10 月 21 日现场加通讯会议的方式召 开，本次会议应出席独立董事 3 人，实际出席独立董事 3 人，符合《公 司章程》和《上市公司独立董事管理办法》的有关规定。本次会议通 知提前以电子邮件及电话通知等方式向全体独立董事送达。公司独立 董事郭珣先生召集和主持了本次会议。 本次独立董事专门会议的召开符合中国证监会《上市公司独立董 事管理办法》及《公司章程》《独立董事工作制度》的有关规定。 二、独立董事专门会议审议情况 经与会 ...

| 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2024-121 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 上海海顺新型药用包装材料股份有限公司 关于使用暂时闲置募集资金购买现金管理产品提前赎回并 继续购买现金管理产品的进展公告 公司子公司浙江海顺新材料有限公司于2024年7月19日使用闲置 募集资金2,500.00万元通过东方财富证券股份有限公司购买东方财 富证券吉祥月月盈151号收益凭证,内容详见公司于2024年7月22日在 巨潮资讯网（http://www.cninfo.com.cn）披露的《上海海顺新型药 用包装材料股份有限公司关于使用部分闲置募集资金进行现金管理 的进展公告》（公告编号：2024-085）。上述理财产品根据收益凭证 产品认购协议已于2024年10月14日敲出，本金2,500.00万元及收益 29.96万元已于10月16日归还至公司募集资金账户。具体赎回情况如 下： | | | 产品类 | 金额 | 期初 | 敲出 | 年化 | 实际收 | | --- | --- | --- | --- | --- | - ...